FIVE PRIME

Written By John McCamant

Our top speculative idea for 2015 a classic early-stage platform; the company is a leader in the discovery of innovative protein therapeutics, explains John McCamant, editor of The Medical Technology Stock Letter.

Five Prime (FPRX) has built an extremely impressive library comprised of more than 5,600 human extracellular proteins, which represents virtually all of the body’s medically important targets for protein therapeutics.

Importantly, the company’s protein technology platform, business model, and intellectual property have all been validated by their impressive list of corporate partners, including Bristol-Myers and Glaxo SmithKline.

In our view, FPRX’s management team has all the right ingredients for success with an experienced roster that has a tremendous track record in bringing protein drugs to the market.

Management execution will be key to FPRX’s future growth and is even more critical in a platform company, which we expect will continue to generate a plethora a partnerships as they fully leverage their cutting edge technology.